Drugs / 68Ga-citrate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05446376 | Nov 2024 → Nov 2026 expected | infective endocarditis | University Hospital, Bordeaux | Recruiting | No outcome recorded |
| Phase 2 | NCT03123289 | Mar 2017 → Oct 2020 | — | Rutgers, The State University of New Jersey | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT04139395 | Jan 2019 → Dec 2020 | unexplained long-lasting fever/inflammatory syndrome | Carina Mari Aparici | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-citrate | “After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously.” NCT03123289 ↗ |
| Known as | Gallium 68 citrate | “PET/CT with Gallium 68 citrate (68Ga-PET/CT) could reduce the number of false negatives while having similar specificity to 18FDG-PET/CT for the diagnosis of infective...” NCT05446376 ↗ |
| Modality | Diagnostic / imaging agent | “This arm, undergoing the "68-Gallium citrate PET/CT scan intervention", includes the PET/CT scans performed with 68Gallium-citrate radiotracer.” NCT03123289 ↗ |
| Route | Intravenous | “Patients disgnosed with fever of unknown origin are injected intravenously (IV) with 370 MBq of 68Ga Citrate.” NCT04139395 ↗ |